PUBLISHED DATE : Feb 2023 | Pages : 402
Fill out your details & get your free sample
The In Vitro Diagnostics Market Size, Share, & Trends Analysis Report By
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023–2028
402 Pages
239 Tables
156 Charts
5 Regions
22 Countries
90 Companies
5 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (2028) | USD 127.56 Billion |
| MARKET SIZE (2022) | USD 105.23 Billion |
| CAGR (2022-2028) | 3.26% |
| BASE YEAR | 2022 |
| FORECAST YEAR | 2023-2028 |
| SEGMENTS BY | Product & Services, Technology, Application, End-Users, and Geography |
| LARGEST REGIONAL MARKET | North America |
| GEOGRAPHIC ANALYSIS | North America, Europe, APAC, Latin America, and Middle East & Africa |
| KEY VENDORS | Abbott, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific |
The global in vitro diagnostics market size was valued at USD 105.23 billion in 2022 and is expected to reach USD 127.56 billion by 2028, growing at a CAGR of 3.26% from 2022 to 2028. The IVD market offers advanced, cost-effective, and fast tools that enable precise diagnosis and point-of-care testing or self-testing. The market has moved from conventional instruments to advanced analyzers that need a small volume of samples and high-throughput screening methodologies. These advances, combined with AI and cloud technology, revolutionize the in vitro diagnostics market. The low-volume sample analysis, automation, high-throughput analysis, rapid analysis times, small footprint, low cost, portability, and disposability are key trends in the IVD market.
IVD are clinical tests that analyze samples taken from people and deliver treatments for specific diseases. Globally, the burden of chronic infectious diseases accelerates the demand for advanced diagnostic services that drive the growth of the in vitro diagnostics market. In the US, the growth of the in vitro diagnostics market is mostly driven by the country's expenditure and awareness of chronic and infectious diseases. Access to diagnosis and care services across the US is significantly higher than in developed countries. With the growing preference for early detection and diagnosis of chronic and infectious diseases, the country's demand for IVD solutions increased. Other than COVID-19 and monkeypox, other infectious diseases, such as HIV, HSV, and chlamydia, are the leading infectious diseases that drive the demand for IVD diagnosis in the country.
Advances in Molecular Diagnostics Transforming the Future of Healthcare
Over the past decade, the healthcare industry witnessed high development and growth in in-vitro diagnostics. Advances in molecular diagnostics are dramatically improving medical treatment outcomes in current times. Due to drug failure in clinical trials and regulatory barriers, bio-pharmaceutical companies are turning toward new medical solutions at the molecular level and molecular diagnostics. In addition, next-generation sequencing and clustered regularly interspaced short palindromic repeats (CRISPER) technology significantly improve molecular diagnostics for oncology and infectious diseases care. Such factors are expected to lead the in vitro diagnostics market in the future.
Increasing Product Launches & Mergers & Acquisitions in IVD
IVD diagnostics is among the biggest industries to witness several product launches in recent years. The increasing demand for new diagnostics tests forces us to develop new solutions. The IVD players are operating in a world that designs, develops, manufactures, and sells best-in-class solutions. COVID-19 is one of the best periods where several companies have come forward to develop rapid test kits to detect coronavirus.
In the first half of 2021, IVD companies reported high revenues due to COVID-19 testing. However, in the year's second half, many companies experienced low demand for COVID-19 testing, resulting in decreased COVID-19 product revenue. In the same period, to increase the production and expansion of distribution networks, IVD companies adopted M&A strategies. To prepare for COVID-19, some major and emerging IVD companies have turned to M&As to increase their diagnostic testing portfolio. These acquisitions witnessed the in vitro diagnostics market expansion and portfolio expansion.
A large patient population with chronic and infectious diseases drives the demand for IVD solutions and fuels market growth.
Chronic diseases such as cancer, diabetes, cardiovascular diseases, and others are public health concerns worldwide, resulting in high demand for diagnostic services. In addition, infectious diseases, such as HIV, COVID-19, influenza, staphylococcus, respiratory syncytial virus, and others, pose significant demand for diagnostic services and fuel market growth.
Adopting advanced technologies in IVD drives significant IVD testing worldwide without experiencing the burden of time and cost. Moreover, they have increased the efficiency of diagnostics and delivered the most accurate results that accelerate market growth. Advances, such as a new generation of IVD products with AI and the digital platform, provide newer dimensions in the global in vitro diagnostics market.
INSIGHTS BY PRODUCTS AND SERVICES
The reagent and consumables are the largest segments, accounting for 66.47% of the global in vitro diagnostics market in 2022. Reagents and consumables are used in IVD procedures as a medium and transporter of specimens of patients with medical conditions for diagnosis, treatments, and monitoring. The reoccurring use of reagents and consumables is driving the market growth. Innovation in consumables, especially reagents, is low compared to analyzers. Some companies do come up with new types of reagents for unique products. For instance, Sysmex, a Japanese company, developed a concentrated reagent for hematology analyzers. These concentrated reagents are gaining traction in the market, especially in developed countries. This is helping the company to gain market share. End-users are shifting toward concentrated reagents, which have more benefits than conventional reagents.
INSIGHTS BY TECHNOLOGY
The global in vitro diagnostics market is segmented into immuno & clinical chemistry, molecular testing, hematology, microbiology & cytology, point- and others by technology. In 2022, the immune & clinical chemistry segment accounted for 45.26% market share of the global IVD market and dominated the other segments. Immunoassay and clinical chemistry are technologies that experience high usage in IVD. These technologies are mostly used to diagnose infectious and chronic diseases that significantly burden global healthcare services. The patient population with chronic and infectious diseases drives the segmental growth of immunochemistry-based IVD solutions. Furthermore, clinical chemistry has wide applications in detecting cancer, diabetes, heart disease, renal disease, liver disorders, and other health conditions that accelerate segmental growth.
INSIGHTS BY APPLICATION
In 2022, in vitro diagnostics applications for infectious diseases accounted for 46.95% market share. The global IVD market application is segmented into infectious diseases, diabetes, cardiology, oncology, autoimmune diseases, nephrology, drug testing, and others by application. During the COVID-19 pandemic, more than 3 to 4 billion tests were conducted worldwide, which fueled the growth of the in-vitro diagnostics market. In addition, HIV, influenza, respiratory syncytial virus, and other infectious diseases drive the demand for IVD and boost industry growth. With the increasing burden of infectious diseases, the demand for diagnosis and treatment continues to rise, thus driving the demand for IVD solutions. In recent years, the development in technologies and increasing integration of new technologies for infectious disease diagnosis have led the market to witness high revenue generation through the infectious diseases segment.
INSIGHTS BY END-USERS
The standard reference labs dominated the end-user segment in the global in vitro diagnostics market and was valued at USD 36 billion in 2022 and is expected to grow impressively by 2028. Standard reference laboratories offer several types of IVD services. In recent years, standard reference laboratories have rapidly expanded in LMICs to offer numerous tests and deliver high market growth through adopting new technologies and product offerings. Standard reference laboratories expand their network in a particular region or concentrated areas and deliver easy access to diagnostic services at affordable prices. In addition, the broad range of diagnosis services increases access to several tests that attract a high consumer base and generate significant revenue. In 2022, the standard reference labs segment accounted for 34.21% of the global IVD market.
The global in-vitro diagnostics market by hospital-affiliated labs was valued at USD 28.54 billion in 2022. Hospitals are the primary source and first point of contact for disease diagnosis and cure. In contrast, hospital-associated laboratories account for the high number of IVD practices and drive segmental growth. Globally, the number of hospitals and associated laboratories, growing infrastructure, and increasing healthcare expenditure are some factors that increase the demand for IVD practices through hospitals.
In 2022, North America dominated the global IVD market accounting for a 39.90% share. A large patient population base with high healthcare expenditures accelerates the region's market growth. In addition, the awareness of disease diagnosis, such as point-of-care, early detection, and preventive health check-ups, are some factors that majorly and positively impact the industry growth in the region. More than 60% to 80% of the regional population have chronic conditions that demand diagnostics services. Expenditure on healthcare services in the region accounted for approximately USD 4.3 trillion and above in 2021, which grew by 2.7% from 2020, indicating a high potential for market growth. Some leading companies, such as Abbott, BD, Bio-Rad Laboratories, and Biomerieux SA, have higher market penetration in the region, especially in the US. They are increasing access to IVD components and accounting for high revenue generation in the country.
Europe is one of the leading and major IVD market regions, accounting for a significant demand for IVD solutions. The factors responsible for the increasing demand for IVD solutions are the growing aging population in the region, with chronic and infectious diseases driving the high demand for IVD solutions. Across Europe, more than 25,000 pathologists are available, while the UK accounts for 40 pathologists per million population. Germany and France accounted for 20 to 29 pathologists per million population. Europe's in vitro diagnostics market is expected to reach USD 31.41 billion by 2028.
The leading players in the global in vitro diagnostics market are F Hoffmann-La Roche, Abbott, Thermo Fisher Scientific, and Siemens Healthineers, which are competing with rapidly emerging market players. Vendors are increasing their industry market share through inorganic growth and a constant product launch, helping the vendors acquire new customers. Abbot is one of the leading companies in the global in vitro diagnostics market and is a pioneer in point-of-care diagnostics with a comprehensive portfolio of tests and systems. Its diagnostic products segment offers core laboratory analyzers and biomarkers (clinical chemistry), immunoassay, hematology, and transfusion. In 2021, the company achieved around USD 15.6 billion in revenue, respectively.
Recent Developments in The Global In Vitro Diagnostics Market
Frequently Asked Questions
How big is the In Vitro Diagnostics Market?
The global in vitro diagnostics market size was valued at USD 105.23 billion in 2022 and is expected to reach USD 127.56 billion by 2028.
What is the growth rate of the in vitro diagnostics market?
The global in vitro diagnostics market share is growing at a CAGR of 3.26% from 2022-2028.
Who are the key players in the global in vitro diagnostics market?
Abbott, Danaher, F. Hoffmann-La Roche, Siemens Healthineers, and Thermo Fisher Scientific are the major players in the global in-vitro diagnostics market.
Which region holds the most significant global in vitro diagnostics market share?
In 2022, North America accounted for the largest global in-vitro diagnostics market accounting for a 39.90% share. Awareness of primary care and point-of-care for those disease conditions fuel the acceptance of IVD solutions and services in the region.
What are the growing trends in the in vitro diagnostics market?
Advances in molecular diagnostics are transforming the future of healthcare, increasing demand for companion diagnostics in IVD, and increasing product launches & mergers & acquisitions are trends in the in-vitro diagnostics market.
The in vitro diagnostics market is expected to grow at a CAGR of approximately 3.26% from 2022 to 2028.
The following factors are likely to contribute to the growth of the in vitro diagnostics market during the forecast period:
Base Year: 2022
Forecast Year: 2023-2028
The report considers the present scenario of the global in vitro diagnostics market and its market dynamics for 2023−2028. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the industry. It also profiles and analyzes leading companies and several other prominent companies operating in the industry.
Key Company Profiles
Other Prominent Vendors
Segmentation By Product & Services
Segmentation By Technology
Segmentation By Application
Segmentation By End-Users
Segmentation by Geography
1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET BY PRODUCT & SERVICES:
4.3.2 MARKET BY TECHNOLOGY
4.3.3 MARKET BY APPLICATION
4.3.4 MARKET BY END-USERS
4.3.5 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 PREMIUM INSIGHTS
7.1 OVERVIEW
8 INTRODUCTION
8.1 OVERVIEW
9 MARKET OPPORTUNITIES & TRENDS
9.1 ADVANCES IN MOLECULAR DIAGNOSTICS TRANSFORMING THE FUTURE OF HEALTHCARE
9.2 INCREASED DEMAND FOR COMPANION DIAGNOSTICS IN IVD
9.3 INCREASING PRODUCT LAUNCHES & MERGERS & ACQUISITIONS IN IVD
10 MARKET GROWTH ENABLERS
10.1 PRESENCE OF A SIGNIFICANT PATIENT POPULATION
10.2 ADOPTION OF ADVANCED TECHNOLOGIES IN IVD
10.3 COVID-19 IMPACT ON IVD MARKET
11 MARKET RESTRAINTS
11.1 STRINGENT REGULATIONS AND ASSOCIATED CHALLENGES
11.2 HIGH COST OF IVD
11.3 LACK OF ACCESS TO DIAGNOSTIC SERVICES AND ASSOCIATED CHALLENGES
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.1.1 INSIGHT BY PRODUCT & SERVICES
12.1.2 INSIGHT BY TECHNOLOGY
12.1.3 INSIGHT BY APPLICATION
12.1.4 INSIGHT BY END-USERS
12.1.5 INSIGHT BY GEOGRAPHY
12.2 MARKET SIZE & FORECAST
12.3 FIVE FORCES ANALYSIS
12.3.1 THREAT OF NEW ENTRANTS
12.3.2 BARGAINING POWER OF SUPPLIERS
12.3.3 BARGAINING POWER OF BUYERS
12.3.4 THREAT OF SUBSTITUTES
12.3.5 COMPETITIVE RIVALRY
13 PRODUCT & SERVICES
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.2 MARKET OVERVIEW
13.3 REAGENTS AND CONSUMABLES
13.3.1 MARKET OVERVIEW
13.3.2 MARKET SIZE & FORECAST
13.3.3 MARKET BY GEOGRAPHY
13.4 INSTRUMENTS/ANALYZERS & SOFTWARE
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY
13.5 SERVICES
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 MARKET BY GEOGRAPHY
14 TECHNOLOGY
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 IMMUNO & CLINICAL CHEMISTRY
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 MOLECULAR DIAGNOSTICS
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
14.5 HEMATOLOGY
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 MARKET BY GEOGRAPHY
14.6 MICROBIOLOGY & CYTOLOGY
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 MARKET BY GEOGRAPHY
14.7 OTHERS
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
14.7.3 MARKET BY GEOGRAPHY
15 APPLICATION
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 INFECTIOUS DISEASES
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 MARKET BY GEOGRAPHY
15.4 DIABETES
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 MARKET BY GEOGRAPHY
15.5 CARDIOLOGY
15.5.1 MARKET OVERVIEW
15.5.2 MARKET SIZE & FORECAST
15.5.3 MARKET BY GEOGRAPHY
15.6 ONCOLOGY
15.6.1 MARKET OVERVIEW
15.6.2 MARKET SIZE & FORECAST
15.6.3 MARKET BY GEOGRAPHY
15.7 AUTOIMMUNE DISEASE
15.7.1 MARKET OVERVIEW
15.7.2 MARKET SIZE & FORECAST
15.7.3 MARKET BY GEOGRAPHY
15.8 NEPHROLOGY
15.8.1 MARKET OVERVIEW
15.8.2 MARKET SIZE & FORECAST
15.8.3 MARKET BY GEOGRAPHY
15.9 DRUG TESTING
15.9.1 MARKET OVERVIEW
15.9.2 MARKET SIZE & FORECAST
15.9.3 MARKET BY GEOGRAPHY
15.10 OTHERS
15.10.1 MARKET OVERVIEW
15.10.2 MARKET SIZE & FORECAST
15.10.3 MARKET BY GEOGRAPHY
16 END-USERS
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 MARKET OVERVIEW
16.3 STANDARD REFERENCE LABS
16.3.1 MARKET OVERVIEW
16.3.2 MARKET SIZE & FORECAST
16.3.3 MARKET BY GEOGRAPHY
16.4 HOSPITAL-AFFILIATED LABS
16.4.1 MARKET OVERVIEW
16.4.2 MARKET SIZE & FORECAST
16.4.3 MARKET BY GEOGRAPHY
16.5 INDIVIDUALS
16.5.1 MARKET OVERVIEW
16.5.2 MARKET SIZE & FORECAST
16.5.3 MARKET BY GEOGRAPHY
16.6 CLINICS
16.6.1 MARKET OVERVIEW
16.6.2 MARKET SIZE & FORECAST
16.6.3 MARKET BY GEOGRAPHY
16.7 OTHERS
16.7.1 MARKET OVERVIEW
16.7.2 MARKET SIZE & FORECAST
16.7.3 MARKET BY GEOGRAPHY
17 GEOGRAPHY
17.1 MARKET SNAPSHOT & GROWTH ENGINE
17.2 GEOGRAPHIC OVERVIEW
18 NORTH AMERICA
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.3 PRODUCT & SERVICES
18.3.1 MARKET SIZE & FORECAST
18.4 TECHNOLOGY
18.4.1 MARKET SIZE & FORECAST
18.5 APPLICATION
18.5.1 MARKET SIZE & FORECAST
18.6 END-USER
18.6.1 MARKET SIZE & FORECAST
18.7 KEY COUNTRIES
18.7.1 US: MARKET SIZE & FORECAST
18.7.2 CANADA: MARKET SIZE & FORECAST
19 EUROPE
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.3 PRODUCT & SERVICES
19.3.1 MARKET SIZE & FORECAST
19.4 TECHNOLOGY
19.4.1 MARKET SIZE & FORECAST
19.5 APPLICATION
19.5.1 MARKET SIZE & FORECAST
19.6 END-USER
19.6.1 MARKET SIZE & FORECAST
19.7 KEY COUNTRIES
19.7.1 GERMANY: MARKET SIZE & FORECAST
19.7.2 FRANCE: MARKET SIZE & FORECAST
19.7.3 RUSSIA: MARKET SIZE & FORECAST
19.7.4 SPAIN: MARKET SIZE & FORECAST
19.7.5 ITALY: MARKET SIZE & FORECAST
19.7.6 UK: MARKET SIZE & FORECAST
20 APAC
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.3 PRODUCT & SERVICES
20.3.1 MARKET SIZE & FORECAST
20.4 TECHNOLOGY
20.4.1 MARKET SIZE & FORECAST
20.5 APPLICATION
20.5.1 MARKET SIZE & FORECAST
20.6 END-USER
20.6.1 MARKET SIZE & FORECAST
20.7 KEY COUNTRIES
20.7.1 CHINA: MARKET SIZE & FORECAST
20.7.2 JAPAN: MARKET SIZE & FORECAST
20.7.3 INDIA: MARKET SIZE & FORECAST
20.7.4 SOUTH KOREA: MARKET SIZE & FORECAST
20.7.5 AUSTRALIA: MARKET SIZE & FORECAST
20.7.6 INDONESIA: MARKET SIZE & FORECAST
20.7.7 MALAYSIA MARKET SIZE & FORECAST
20.7.8 SINGAPORE MARKET SIZE & FORECAST
21 LATIN AMERICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.3 PRODUCT & SERVICES
21.3.1 MARKET SIZE & FORECAST
21.4 TECHNOLOGY
21.4.1 MARKET SIZE & FORECAST
21.5 APPLICATION
21.5.1 MARKET SIZE & FORECAST
21.6 END-USER
21.6.1 MARKET SIZE & FORECAST
21.7 KEY COUNTRIES
21.7.1 BRAZIL: MARKET SIZE & FORECAST
21.7.2 MEXICO: MARKET SIZE & FORECAST
21.7.3 ARGENTINA: MARKET SIZE & FORECAST
22 MIDDLE EAST & AFRICA
22.1 MARKET OVERVIEW
22.2 MARKET SIZE & FORECAST
22.3 PRODUCT & SERVICES
22.3.1 MARKET SIZE & FORECAST
22.4 TECHNOLOGY
22.4.1 MARKET SIZE & FORECAST
22.5 APPLICATION
22.5.1 MARKET SIZE & FORECAST
22.6 END-USER
22.6.1 MARKET SIZE & FORECAST
22.7 KEY COUNTRIES
22.7.1 TURKEY: MARKET SIZE & FORECAST
22.7.2 SAUDI ARABIA: MARKET SIZE & FORECAST
22.7.3 SOUTH AFRICA: MARKET SIZE & FORECAST
23 COMPETITIVE LANDSCAPE
23.1 COMPETITION OVERVIEW
23.2 MARKET SHARE ANALYSIS
23.2.1 ABBOTT
23.2.2 DANAHER
23.2.3 F. HOFFMANN-LA ROCHE
23.2.4 SIEMENS HEALTHINEERS
23.2.5 THERMO FISHER SCIENTIFIC
24 KEY COMPANY PROFILES
24.1 ABBOTT
24.1.1 BUSINESS OVERVIEW
24.1.2 PRODUCT OFFERINGS
24.1.3 KEY STRATEGIES
24.1.4 KEY STRENGTHS
24.1.5 KEY OPPORTUNITIES
24.2 DANAHER
24.2.1 BUSINESS OVERVIEW
24.2.2 PRODUCT OFFERINGS
24.2.3 KEY STRATEGIES
24.2.4 KEY STRENGTHS
24.2.5 KEY OPPORTUNITIES
24.3 F. HOFFMANN-LA ROCHE
24.3.1 BUSINESS OVERVIEW
24.3.2 PRODUCT OFFERINGS
24.3.3 KEY STRATEGIES
24.3.4 KEY STRENGTHS
24.3.5 KEY OPPORTUNITIES
24.4 SIEMENS HEALTHINEERS
24.4.1 BUSINESS OVERVIEW
24.4.2 PRODUCT OFFERINGS
24.4.3 KEY STRATEGIES
24.4.4 KEY STRENGTHS
24.4.5 KEY OPPORTUNITIES
24.5 THERMO FISHER SCIENTIFIC
24.5.1 BUSINESS OVERVIEW
24.5.2 PRODUCT OFFERINGS
24.5.3 KEY STRATEGIES
24.5.4 KEY STRENGTHS
24.5.5 KEY OPPORTUNITIES
25 OTHER PROMINENT VENDORS
25.1 ATOMO DIAGNOSTICS
25.1.1 BUSINESS OVERVIEW
25.1.2 PRODUCT OFFERINGS
25.2 ACCELERATE DIAGNOSTICS
25.2.1 BUSINESS OVERVIEW
25.2.2 PRODUCT OFFERINGS
25.3 AGILENT TECHNOLOGIES
25.3.1 BUSINESS OVERVIEW
25.3.2 PRODUCT OFFERINGS
25.4 ALTONA DIAGNOSTICS
25.4.1 BUSINESS OVERVIEW
25.4.2 PRODUCT OFFERINGS
25.5 AMOY DIAGNOSTICS
25.5.1 BUSINESS OVERVIEW
25.5.2 PRODUCT OFFERINGS
25.6 ARKRAY
25.6.1 BUSINESS OVERVIEW
25.6.2 PRODUCT OFFERINGS
25.7 ACCUBIOTECH
25.7.1 BUSINESS OVERVIEW
25.7.2 PRODUCT OFFERINGS
25.8 AGAPPE DIAGNOSTICS
25.8.1 BUSINESS OVERVIEW
25.8.2 PRODUCT OFFERINGS
25.9 BD
25.9.1 BUSINESS OVERVIEW
25.9.2 PRODUCT OFFERINGS
25.10 BIO-RAD LABORATORIES
25.10.1 BUSINESS OVERVIEW
25.10.2 PRODUCT OFFERINGS
25.11 BALIO DIAGNOSTICS
25.11.1 BUSINESS OVERVIEW
25.11.2 PRODUCT OFFERINGS
25.12 B&E BIO-TECHNOLOGY
25.12.1 BUSINESS OVERVIEW
25.12.2 PRODUCT OFFERINGS
25.13 BIOMÉRIEUX
25.13.1 BUSINESS OVERVIEW
25.13.2 PRODUCT OFFERINGS
25.14 BIOLYTICAL LABORATORIES
25.14.1 BUSINESS OVERVIEW
25.14.2 PRODUCT OFFERINGS
25.15 BIOSYNEX
25.15.1 BUSINESS OVERVIEW
25.15.2 PRODUCT OFFERINGS
25.16 BIOCARTIS
25.16.1 BUSINESS OVERVIEW
25.16.2 PRODUCT OFFERINGS
25.17 BIOCEPT
25.17.1 BUSINESS OVERVIEW
25.17.2 PRODUCT OFFERINGS
25.18 BIOHIT OYJ
25.18.1 BUSINESS OVERVIEW
25.18.2 PRODUCT OFFERINGS
25.19 BIOMERICA
25.19.1 BUSINESS OVERVIEW
25.19.2 PRODUCT OFFERINGS
25.20 BIOSYSTEM
25.20.1 BUSINESS OVERVIEW
25.20.2 PRODUCT OFFERINGS
25.21 BIOWAY BIOLOGICAL TECHNOLOGY
25.21.1 BUSINESS OVERVIEW
25.21.2 PRODUCT OFFERINGS
25.22 BOULE DIAGNOSTICS
25.22.1 BUSINESS OVERVIEW
25.22.2 PRODUCT OFFERINGS
25.23 CUPID LIMITED
25.23.1 BUSINESS OVERVIEW
25.23.2 PRODUCT OFFERINGS
25.24 CAREDX
25.24.1 BUSINESS OVERVIEW
25.24.2 PRODUCT OFFERINGS
25.25 CHEMBIO DIAGNOSTICS
25.25.1 BUSINESS OVERVIEW
25.25.2 PRODUCT OFFERINGS
25.26 CLINDIAG SYSTEMSA
25.26.1 BUSINESS OVERVIEW
25.26.2 PRODUCT OFFERINGS
25.27 CONTEC MEDICAL SYSTEMS
25.27.1 BUSINESS OVERVIEW
25.27.2 PRODUCT OFFERINGS
25.28 CONVERGENT TECHNOLOGIES
25.28.1 BUSINESS OVERVIEW
25.28.2 PRODUCT OFFERINGS
25.29 CPC DIAGNOSTICS
25.29.1 BUSINESS OVERVIEW
25.29.2 PRODUCT OFFERINGS
25.30 CPM SCIENTIFICA
25.30.1 BUSINESS OVERVIEW
25.30.2 PRODUCT OFFERINGS
25.31 CELLAVISION
25.31.1 BUSINESS OVERVIEW
25.31.2 PRODUCT OFFERINGS
25.32 DIALAB
25.32.1 BUSINESS OVERVIEW
25.32.2 PRODUCT OFFERINGS
25.33 DEXCOM
25.33.1 BUSINESS OVERVIEW
25.33.2 PRODUCT OFFERINGS
25.34 DIASORIN
25.34.1 BUSINESS OVERVIEW
25.34.2 PRODUCT OFFERINGS
25.35 DIAGON
25.35.1 BUSINESS OVERVIEW
25.35.2 PRODUCT OFFERINGS
25.36 DIATRON
25.36.1 BUSINESS OVERVIEW
25.36.2 PRODUCT OFFERINGS
25.37 DIRUI
25.37.1 BUSINESS OVERVIEW
25.37.2 PRODUCT OFFERINGS
25.38 DRUCKER DIAGNOSTICS
25.38.1 BUSINESS OVERVIEW
25.38.2 PRODUCT OFFERINGS
25.39 EDAN INSTRUMENTS
25.39.1 BUSINESS OVERVIEW
25.39.2 PRODUCT OFFERINGS
25.40 EKF DIAGNOSTICS HOLDING
25.40.1 BUSINESS OVERVIEW
25.40.2 PRODUCT OFFERINGS
25.41 ELITECHGROUP
25.41.1 BUSINESS OVERVIEW
25.41.2 PRODUCT OFFERINGS
25.42 ERBA DIAGNOSTICS
25.42.1 BUSINESS OVERVIEW
25.42.2 PRODUCT OFFERINGS
25.43 GENETRON HOLDINGS
25.43.1 BUSINESS OVERVIEW
25.43.2 PRODUCT OFFERINGS
25.44 GENRUI BIOTECH
25.44.1 BUSINESS OVERVIEW
25.44.2 PRODUCT OFFERINGS
25.45 HOLOGIC
25.45.1 BUSINESS OVERVIEW
25.45.2 PRODUCT OFFERINGS
25.46 HIGH TECHNOLOGY
25.46.1 BUSINESS OVERVIEW
25.46.2 PRODUCT OFFERINGS
25.47 HORIBA
25.47.1 BUSINESS OVERVIEW
25.47.2 PRODUCT OFFERINGS
25.48 LINEAR CHEMICALS
25.48.1 BUSINESS OVERVIEW
25.48.2 PRODUCT OFFERINGS
25.49 ILLUMINA
25.49.1 BUSINESS OVERVIEW
25.49.2 PRODUCT OFFERINGS
25.50 INTEC
25.50.1 BUSINESS OVERVIEW
25.50.2 PRODUCT OFFERINGS
25.51 J. MITRA & CO.
25.51.1 BUSINESS OVERVIEW
25.51.2 PRODUCT OFFERINGS
25.52 KILPEST INDIA LIMITED
25.52.1 BUSINESS OVERVIEW
25.52.2 PRODUCT OFFERINGS
25.53 MACCURA BIOTECHNOLOGY
25.53.1 BUSINESS OVERVIEW
25.53.2 PRODUCT OFFERINGS
25.54 MEDSOURCE OZONE BIOMEDICALS
25.54.1 BUSINESS OVERVIEW
25.54.2 PRODUCT OFFERINGS
25.55 MERIL LIFE SCIENCES
25.55.1 BUSINESS OVERVIEW
25.55.2 PRODUCT OFFERINGS
25.56 MP BIOMEDICALS
25.56.1 BUSINESS OVERVIEW
25.56.2 PRODUCT OFFERINGS
25.57 NANJING SYNTHGENE MEDICAL TECHNOLOGY
25.57.1 BUSINESS OVERVIEW
25.57.2 PRODUCT OFFERINGS
25.58 NIHON KOHDEN
25.58.1 BUSINESS OVERVIEW
25.58.2 PRODUCT OFFERINGS
25.59 NORMA INSTRUMENTS
25.59.1 BUSINESS OVERVIEW
25.59.2 PRODUCT OFFERINGS
25.60 NOWDIAGNOSTICS
25.60.1 BUSINESS OVERVIEW
25.60.2 PRODUCT OFFERINGS
25.61 ORTHO CLINICAL DIAGNOSTICS
25.61.1 BUSINESS OVERVIEW
25.61.2 PRODUCT OFFERINGS
25.62 OPKO HEALTH (BIOREFERENCE HEALTH)
25.62.1 BUSINESS OVERVIEW
25.62.2 PRODUCT OFFERINGS
25.63 ORASURE TECHNOLOGIES
25.63.1 BUSINESS OVERVIEW
25.63.2 PRODUCT OFFERINGS
25.64 PERKIN ELMER
25.64.1 BUSINESS OVERVIEW
25.64.2 PRODUCT OFFERINGS
25.65 PRESTIGE DIAGNOSTICS
25.65.1 BUSINESS OVERVIEW
25.65.2 PRODUCT OFFERINGS
25.66 QIAGEN
25.66.1 BUSINESS OVERVIEW
25.66.2 PRODUCT OFFERINGS
25.67 QUIDEL
25.67.1 BUSINESS OVERVIEW
25.67.2 PRODUCT OFFERINGS
25.68 SYSMEX
25.68.1 BUSINESS OVERVIEW
25.68.2 PRODUCT OFFERINGS
25.69 SALOFA OY
25.69.1 BUSINESS OVERVIEW
25.69.2 PRODUCT OFFERINGS
25.70 SEASUN BIOMATERIALS
25.70.1 BUSINESS OVERVIEW
25.70.2 PRODUCT OFFERINGS
25.71 SEKISUI DIAGNOSTICS
25.71.1 BUSINESS OVERVIEW
25.72 SFRI
25.72.1 BUSINESS OVERVIEW
25.72.2 PRODUCT OFFERINGS
25.73 SHENZHEN DYMIND BIOTECHNOLOGY
25.73.1 BUSINESS OVERVIEW
25.73.2 PRODUCT OFFERINGS
25.74 SHENZHEN ICUBIO BIOMEDICAL TECHNOLOGY
25.74.1 BUSINESS OVERVIEW
25.74.2 PRODUCT OFFERINGS
25.75 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS
25.75.1 BUSINESS OVERVIEW
25.75.2 PRODUCT OFFERINGS
25.76 SHENZHEN PROKAN ELECTRONICS
25.76.1 BUSINESS OVERVIEW
25.76.2 PRODUCT OFFERINGS
25.77 SHENZHEN LANDWIND MEDICAL
25.77.1 BUSINESS OVERVIEW
25.77.2 PRODUCT OFFERINGS
25.78 SINOCARE
25.78.1 BUSINESS OVERVIEW
25.78.2 PRODUCT OFFERINGS
25.79 SPINREACT
25.79.1 BUSINESS OVERVIEW
25.79.2 PRODUCT OFFERINGS
25.80 SURESCREEN DIAGNOSTICS
25.80.1 BUSINESS OVERVIEW
25.80.2 PRODUCT OFFERINGS
25.81 THE BINDING SITE GROUP
25.81.1 BUSINESS OVERVIEW
25.81.2 PRODUCT OFFERINGS
25.82 TRINITY BIOTECH
25.82.1 BUSINESS OVERVIEW
25.82.2 PRODUCT OFFERINGS
25.83 TRIVITRON HEALTHCARE
25.83.1 BUSINESS OVERVIEW
25.83.2 PRODUCT OFFERINGS
25.84 XIAMEN BIOTIME BIOTECHNOLOGY
25.84.1 BUSINESS OVERVIEW
25.84.2 PRODUCT OFFERINGS
25.85 ZHEJIANG ORIENT GENE BIOTECH
25.85.1 BUSINESS OVERVIEW
25.85.2 PRODUCT OFFERINGS
26 REPORT SUMMARY
26.1 KEY TAKEAWAYS
26.2 STRATEGIC RECOMMENDATIONS
27 QUANTITATIVE SUMMARY
27.1 MARKET BY GEOGRAPHY
27.2 MARKET BY PRODUCT & SERVICES
27.3 MARKET BY TECHNOLOGY
27.4 MARKET BY APPLICATION
27.5 MARKET BY END-USERS
27.6 PRODUCT & SERVICES: MARKET BY GEOGRAPHY
27.6.1 REAGENTS & CONSUMABLES: MARKET BY GEOGRAPHY
27.6.2 INSTRUMENTS/ANALYZERS & SOFTWARE: MARKET BY GEOGRAPHY
27.6.3 SERVICES: MARKET BY GEOGRAPHY
27.7 TECHNOLOGY: MARKET BY GEOGRAPHY
27.7.1 IMMUNO & CLINICAL CHEMISTRY: MARKET BY GEOGRAPHY
27.7.2 MOLECULAR DIAGNOSTICS: MARKET BY GEOGRAPHY
27.7.3 HEMATOLOGY: MARKET BY GEOGRAPHY
27.7.4 MICROBIOLOGY & CYTOLOGY: MARKET BY GEOGRAPHY
27.7.5 OTHER TECHNOLOGIES: MARKET BY GEOGRAPHY
27.8 APPLICATION: MARKET BY GEOGRAPHY
27.8.1 INFECTIOUS DISEASES: MARKET BY GEOGRAPHY
27.8.2 DIABETES: MARKET BY GEOGRAPHY
27.8.3 CARDIOLOGY: MARKET BY GEOGRAPHY
27.8.4 ONCOLOGY: MARKET BY GEOGRAPHY
27.8.5 AUTOIMMUNE DISEASES: MARKET BY GEOGRAPHY
27.8.6 NEPHROLOGY: MARKET BY GEOGRAPHY
27.8.7 DRUG TESTING: MARKET BY GEOGRAPHY
27.8.8 OTHER APPLICATIONS: MARKET BY GEOGRAPHY
27.9 END-USERS: MARKET BY GEOGRAPHY
27.9.1 STANDARD REFERENCE LABS: MARKET BY GEOGRAPHY
27.9.2 HOSPITAL AFFILIATED LABS: MARKET BY GEOGRAPHY
27.9.3 INDIVIDUALS: MARKET BY GEOGRAPHY
27.9.4 CLINICS: MARKET BY GEOGRAPHY
27.9.5 OTHER END-USERS: MARKET BY GEOGRAPHY
28 APPENDIX
28.1 ABBREVIATIONS
LIST OF EXHIBITS
EXHIBIT 1 SEGMENTATION OF GLOBAL IN-VITRO DIAGNOSTICS MARKET
EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
EXHIBIT 3 CURRENT & EMERGING MARKET TRENDS
EXHIBIT 4 GLOBAL IN-VITRO DIAGNOSTICS MARKET SEGMENTATION
EXHIBIT 5 MAJOR TRENDS IN IN-VITRO DIAGNOSTICS INDUSTRY
EXHIBIT 6 IMPACT OF ADVANCES IN MOLECULAR DIAGNOSTICS TRANSFORMING THE FUTURE OF HEALTHCARE
EXHIBIT 7 IMPACT OF INCREASED DEMAND FOR COMPANION DIAGNOSTICS IN IVD
EXHIBIT 8 SOME OF THE KEY TECHNOLOGY TRENDS IN COMPANION DIAGNOSTICS
EXHIBIT 9 IMPACT OF INCREASING PRODUCT LAUNCHES & MERGERS & ACQUISITIONS IN IVD
EXHIBIT 10 IMPACT OF PRESENCE OF A SIGNIFICANT PATIENT POPULATION
EXHIBIT 11 CANCER NEW CASES STATISTICS 2020 BY REGIONS
EXHIBIT 12 GLOBAL RARE DISEASES STATISTICS OVERVIEW
EXHIBIT 13 IMPACT OF ADOPTION OF ADVANCED TECHNOLOGIES IN IVD
EXHIBIT 14 CLINICAL LABORATORY ENGAGEMENT WITH AI 2018
EXHIBIT 15 IMPACT OF COVID-19 IMPACTS ON IVD ACCEPTANCE
EXHIBIT 16 UNICEF SARS-COV-2 RRT-PCR TEST FOR AUTOMATED USE 2020 SEPTEMBER -2021 (MILLION)
EXHIBIT 17 IMPACT OF STRINGENT REGULATION AND ASSOCIATED CHALLENGES
EXHIBIT 18 IMPACT OF HIGH COST OF IVD
EXHIBIT 19 IMPACT OF LACK OF ACCESS TO DIAGNOSTIC SERVICES AND ASSOCIATED CHALLENGES
EXHIBIT 20 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028
EXHIBIT 21 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028
EXHIBIT 22 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028
EXHIBIT 23 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022-2028
EXHIBIT 24 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028
EXHIBIT 25 GLOBAL IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)
EXHIBIT 26 FIVE FORCES ANALYSIS 2022
EXHIBIT 27 INCREMENTAL GROWTH BY PRODUCT &SERVICES 2022 & 2028
EXHIBIT 28 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022-2028
EXHIBIT 29 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCTS & SERVICES: MARKET OVERVIEW
EXHIBIT 30 GLOBAL IVD MARKET BY PRODUCTS & SERVICES: INCREMENTAL GROWTH
EXHIBIT 31 GLOBAL IVD MARKET BY PRODUCTS & SERVICES: ABSOLUTE GROWTH
EXHIBIT 32 GLOBAL IVD MARKET BY REAGENTS & CONSUMABLES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 33 GLOBAL IVD MARKET BY REAGENTS & CONSUMABLES 2022–2028 ($ BILLION)
EXHIBIT 34 GLOBAL IVD MARKET BY INSTRUMENT/ANALYZERS & SOFTWARE: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 35 GLOBAL IVD MARKET BY INSTRUMENTS/ ANALYZERS & SOFTWARE 2022–2028 ($ BILLION)
EXHIBIT 36 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY SERVICES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 37 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY SERVICES 2022–2028 ($ BILLION)
EXHIBIT 38 INCREMENTAL GROWTH BY TECHNOLOGY 2022 & 2028
EXHIBIT 39 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022-2028
EXHIBIT 40 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY: MARKET OVERVIEW
EXHIBIT 41 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY: INCREMENTAL GROWTH
EXHIBIT 42 GLOBAL IVD MARKET BY TECHNOLOGY: ABSOLUTE GROWTH
EXHIBIT 43 DIABETES ESTIMATED & PROJECTED PATIENT POPULATION: OPPORTUNITIES FOR SELF-MONITORING TEST
EXHIBIT 44 GLOBAL IVD MARKET BY IMMUNO & CLINICAL CHEMISTRY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 45 GLOBAL IVD MARKET BY IMMUNO & CLINICAL CHEMISTRY 2022–2028 ($ BILLION)
EXHIBIT 46 GLOBAL IVD MARKET BY MOLECULAR DIAGNOSTICS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 47 GLOBAL IVD MARKET BY MOLECULAR DIAGNOSTICS 2022–2028 ($ BILLION)
EXHIBIT 48 GLOBAL IVD MARKET BY HEMATOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 49 GLOBAL IVD MARKET BY HEMATOLOGY 2022–2028 ($ BILLION)
EXHIBIT 50 COMPARISON OF CURRENT & DEVELOPING DIAGNOSTICS BY COST & COMPLEXITY 2021
EXHIBIT 51 GLOBAL IVD MARKET BY MICROBIOLOGY & CYTOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 52 GLOBAL IVD MARKET BY MICROBIOLOGY & CYTOLOGY 2022–2028 ($ BILLION)
EXHIBIT 53 SYSMEX CORPORATION HEMOSTASIS BUSINESS SALE 2018 TO 2021 ($ BILLION)
EXHIBIT 54 ADVANTAGES OF URINALYSIS OVER BLOOD TESTING
EXHIBIT 55 GLOBAL IVD MARKET BY OTHER TECHNOLOGIES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 56 GLOBAL IVD MARKET BY OTHER TECHNOLOGY 2022–2028 ($ BILLION)
EXHIBIT 57 INCREMENTAL GROWTH BY APPLICATIONS 2022 & 2028
EXHIBIT 58 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022-2028
EXHIBIT 59 GLOBAL IVD MARKET BY APPLICATION: MARKET OVERVIEW
EXHIBIT 60 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION: INCREMENTAL GROWTH
EXHIBIT 61 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION: ABSOLUTE GROWTH
EXHIBIT 62 DAILY COVID-19 CASES 2020-2022
EXHIBIT 63 HIV PATIENT POPULATION BY REGION 2021 (MILLION)
EXHIBIT 64 GLOBAL IVD MARKET BY INFECTIOUS DISEASES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 65 GLOBAL IVD MARKET BY INFECTIOUS DISEASES 2022–2028 ($ BILLION)
EXHIBIT 66 NO. OF PEOPLE WITH DIABETES & PER IDF REGION 2021-2045 (20-79 YEARS)
EXHIBIT 67 DIABETES PREVALENCE BY INCOME OF COUNTRIES 2021 & 2025
EXHIBIT 68 GLOBAL IVD MARKET BY DIABETES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 69 GLOBAL IVD MARKET BY DIABETES 2022–2028 ($ BILLION)
EXHIBIT 70 GLOBAL IVD MARKET BY CARDIOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 71 GLOBAL IVD MARKET BY CARDIOLOGY 2022–2028 ($ BILLION)
EXHIBIT 72 NEW CANCER CASES BY TYPE 2020
EXHIBIT 73 GLOBAL IVD MARKET BY ONCOLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 74 GLOBAL IVD MARKET BY ONCOLOGY 2022–2028 ($ BILLION)
EXHIBIT 75 GLOBAL IVD MARKET BY AUTOIMMUNE DISEASES: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 76 GLOBAL IVD MARKET BY AUTOIMMUNE DISEASES 2022–2028 ($ BILLION)
EXHIBIT 77 GLOBAL EPIDEMIOLOGY OF CHRONIC KIDNEY DISEASE (CKD): AN UPDATE 2022
EXHIBIT 78 GLOBAL IVD MARKET BY NEPHROLOGY: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 79 GLOBAL IVD MARKET BY NEPHROLOGY 2022–2028 ($ BILLION)
EXHIBIT 80 COMPARISON OF RAPID & LAB-BASED DRUG SCREENING IN URINE SAMPLE BASED ON TURNAROUND TIME (MINUTES)
EXHIBIT 81 GLOBAL IVD MARKET BY DRUG TESTING: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 82 GLOBAL IVD MARKET BY DRUG TESTING 2022–2028 ($ BILLION)
EXHIBIT 83 GLOBAL IVD MARKET BY OTHER APPLICATIONS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 84 GLOBAL IVD MARKET BY OTHER APPLICATION 2022–2028 ($ BILLION)
EXHIBIT 85 INCREMENTAL GROWTH BY END-USERS 2022 & 2028
EXHIBIT 86 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022-2028
EXHIBIT 87 GLOBAL IVD MARKET BY END-USERS: MARKET OVERVIEW
EXHIBIT 88 GLOBAL IVD MARKET BY END-USERS: INCREMENTAL GROWTH
EXHIBIT 89 GLOBAL IVD MARKET BY END-USER: ABSOLUTE GROWTH
EXHIBIT 90 GLOBAL IVD MARKET BY STANDARD REFERENCE LABS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 91 GLOBAL IVD MARKET BY STANDARD REFERENCE LABS 2022–2028 ($ BILLION)
EXHIBIT 92 GLOBAL IVD MARKET BY HOSPITAL AFFILIATED LABS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 93 GLOBAL IVD MARKET BY HOSPITAL AFFILIATED LABS 2022–2028 ($ BILLION)
EXHIBIT 94 GLOBAL IVD MARKET BY INDIVIDUAL: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 95 GLOBAL IVD MARKET BY INDIVIDUALS 2022–2028 ($ BILLION)
EXHIBIT 96 GLOBAL IVD MARKET BY CLINICS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 97 GLOBAL IVD MARKET BY CLINICS 2022–2028 ($ BILLION)
EXHIBIT 98 GLOBAL IVD MARKET BY OTHER END-USERS: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 99 GLOBAL IVD MARKET BY OTHER END-USERS 2022–2028 ($ BILLION)
EXHIBIT 100 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2028
EXHIBIT 101 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022-2028
EXHIBIT 102 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY: MARKET OVERVIEW
EXHIBIT 103 PRODUCT LIFE CYCLE IN VARIOUS REGIONS – IVD MARKET
EXHIBIT 104 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY: INCREMENTAL GROWTH
EXHIBIT 105 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY: ABSOLUTE GROWTH
EXHIBIT 106 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
EXHIBIT 107 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 108 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)
EXHIBIT 109 INCREMENTAL GROWTH IN NORTH AMERICA 2022 & 2028
EXHIBIT 110 US: HEALTH CONDITIONS & PREVALENCE 2019 TO 2022
EXHIBIT 111 IN-VITRO DIAGNOSTICS MARKET IN THE US 2022–2028 ($ BILLION)
EXHIBIT 112 IN-VITRO DIAGNOSTICS MARKET IN CANADA 2022–2028 ($ BILLION)
EXHIBIT 113 EUROPE IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
EXHIBIT 114 POTENTIAL EFFECT OF IVDR ON LDTS IN CLINICAL LABS
EXHIBIT 115 EUROPE IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 116 EUROPE IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)
EXHIBIT 117 INCREMENTAL GROWTH IN EUROPE 2022 & 2028
EXHIBIT 118 GERMANY: PEOPLE LIVING WITH HIV AND NEW HIV INFECTION CASES 2015 TO 2020
EXHIBIT 119 IN-VITRO DIAGNOSTICS MARKET IN GERMANY 2022–2028 ($ BILLION)
EXHIBIT 120 IN-VITRO DIAGNOSTICS MARKET IN FRANCE 2022-2028 ($ BILLION)
EXHIBIT 121 IN-VITRO DIAGNOSTICS MARKET IN RUSSIA 2022–2028 ($ BILLION)
EXHIBIT 122 IN-VITRO DIAGNOSTICS MARKET IN SPAIN 2022–2028 ($ BILLION)
EXHIBIT 123 IN-VITRO DIAGNOSTICS MARKET IN ITALY 2022–2028 ($ BILLION)
EXHIBIT 124 IN-VITRO DIAGNOSTICS MARKET IN THE UK 2022–2028 ($ BILLION)
EXHIBIT 125 APAC IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
EXHIBIT 126 APAC IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 127 APAC IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)
EXHIBIT 128 INCREMENTAL GROWTH IN APAC 2022 & 2028
EXHIBIT 129 IN-VITRO DIAGNOSTICS MARKET IN CHINA 2022–2028 ($ BILLION)
EXHIBIT 130 IN-VITRO DIAGNOSTICS MARKET JAPAN 2022–2028 ($ BILLION)
EXHIBIT 131 IN-VITRO DIAGNOSTICS MARKET IN INDIA 2022–2028 ($ BILLION)
EXHIBIT 132 IN-VITRO DIAGNOSTICS MARKET IN SOUTH KOREA 2022–2028 ($ BILLION)
EXHIBIT 133 IN-VITRO DIAGNOSTICS MARKET IN AUSTRALIA 2022–2028 ($ BILLION)
EXHIBIT 134 TOTAL HIV CASES IN INDONESIA 2010-2021
EXHIBIT 135 IN-VITRO DIAGNOSTICS MARKET IN INDONESIA 2022–2028 ($ BILLION)
EXHIBIT 136 IN-VITRO DIAGNOSTICS MARKET IN MALAYSIA 2022–2028 ($ BILLION)
EXHIBIT 137 IN-VITRO DIAGNOSTICS MARKET IN SINGAPORE 2022–2028 ($ BILLION)
EXHIBIT 138 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
EXHIBIT 139 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 140 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)
EXHIBIT 141 INCREMENTAL GROWTH IN LATIN AMERICA 2022 & 2028
EXHIBIT 142 IN-VITRO DIAGNOSTICS MARKET IN BRAZIL 2022–2028 ($ BILLION)
EXHIBIT 143 IN-VITRO DIAGNOSTICS MARKET MEXICO 2022–2028 ($ BILLION)
EXHIBIT 144 IN-VITRO DIAGNOSTICS MARKET ARGENTINA 2022–2028 ($ BILLION)
EXHIBIT 145 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET: KEY COUNTRIES
EXHIBIT 146 MIDDLE EAST & AFRICA NATIONAL HIVST POLICY & IMPLEMENTATION 2020
EXHIBIT 147 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET: INCREMENTAL GROWTH & ABSOLUTE GROWTH
EXHIBIT 148 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET 2022–2028 ($ BILLION)
EXHIBIT 149 INCREMENTAL GROWTH IN MIDDLE EAST & AFRICA 2022 & 2028
EXHIBIT 150 IN-VITRO DIAGNOSTICS MARKET IN TURKEY 2022–2028 ($ BILLION)
EXHIBIT 151 IN-VITRO DIAGNOSTICS MARKET SAUDI ARABIA 2022–2028 ($ BILLION)
EXHIBIT 152 IN-VITRO DIAGNOSTICS MARKET SOUTH AFRICA 2022–2028 ($ BILLION)
EXHIBIT 153 GLOBAL IVD MARKET DOMINANCE ANALYSIS
EXHIBIT 154 GLOBAL IVD MARKET DOMINANCE ANALYSIS
EXHIBIT 155 VENDORS OFFERING IVD SOLUTIONS: CAPABILITIES & EXPERTISE ASSESSMENT
EXHIBIT 156 MARKET SHARE & PENETRATION ANALYSIS BASED ON THE REVENUE OF THE MARKET PLAYERS 2020
LIST OF TABLES
TABLE 1 KEY CAVEATS
TABLE 2 CURRENCY CONVERSION 2015−2022
TABLE 3 LIST OF APPROVED/CLEARED COMPANION DIAGNOSTIC DEVICES (IVD)
TABLE 4 LEADING COMPANIES WITH NEW IVD PRODUCTS LAUNCHED 2021-2022
TABLE 5 LEADING COMPANIES WITH NEW IVD PRODUCTS LAUNCHED 2021-2022
TABLE 6 SARS-COV-2 DIAGNOSTICS TEST TYPE
TABLE 7 GLOBAL IVD REAGENTS AND CONSUMABLES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 8 GLOBAL IVD REAGENTS AND CONSUMABLES MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 9 GLOBAL IVD INSTRUMENTS/ANALYZERS & SOFTWARE MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 10 GLOBAL IVD INSTRUMENTS/ANALYZERS & SOFTWARE MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 11 GLOBAL IVD SERVICES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 12 GLOBAL IVD SERVICES MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 13 GLOBAL IVD IMMUNO & CLINICAL CHEMISTRY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 14 GLOBAL IVD IMMUNO & CLINICAL CHEMISTRY MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 15 GLOBAL IVD MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 16 GLOBAL IVD MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 17 GLOBAL IVD HEMATOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 18 GLOBAL IVD HEMATOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 19 GLOBAL IVD MICROBIOLOGY & CYTOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 20 GLOBAL IVD MICROBIOLOGY & CYTOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 21 GLOBAL IVD OTHERS TECHNOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 22 GLOBAL IVD OTHERS TECHNOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 23 COVID-19 PATIENT POPULATION & TOTAL TEST PERFORMED 2020-2022
TABLE 24 GLOBAL IVD INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 25 GLOBAL IVD INFECTIOUS DISEASES MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 26 UNDIAGNOSED DIABETES PATIENT POPULATION CLASSIFICATION BASED ON ECONOMIC STATUS OF COUNTRIES 2021
TABLE 27 GLOBAL IVD DIABETES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 28 GLOBAL IVD DIABETES MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 29 GLOBAL IVD CARDIOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 30 GLOBAL IVD CARDIOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 31 GLOBAL IVD ONCOLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 32 GLOBAL IVD ONCOLOGY MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 33 GLOBAL IVD AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 34 GLOBAL IVD AUTOIMMUNE DISEASES MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 35 GLOBAL CHRONIC KIDNEY FAILURE PATIENT POPULATION
TABLE 36 GLOBAL IVD NEPHROLOGY MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 37 GLOBAL IVD NEPHROLOGY MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 38 GLOBAL IVD DRUG TESTING MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 39 GLOBAL IVD DRUG TESTING MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 40 GLOBAL IVD OTHER APPLICATIONS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 41 GLOBAL IVD OTHER APPLICATIONS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 42 GLOBAL IVD STANDARD REFERENCE LABS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 43 GLOBAL IVD STANDARD REFERENCE LABS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 44 GLOBAL IVD HOSPITAL AFFILIATED LABS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 45 GLOBAL IVD HOSPITAL AFFILIATED LABS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 46 GLOBAL IVD INDIVIDUALS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 47 GLOBAL IVD INDIVIDUALS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 48 GLOBAL IVD CLINICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 49 GLOBAL IVD CLINICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 50 GLOBAL IVD OTHER END-USERS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 51 GLOBAL IVD OTHER END-USERS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 52 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)
TABLE 53 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)
TABLE 54 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)
TABLE 55 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 56 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 57 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)
TABLE 58 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 59 NORTH AMERICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 60 US: CANCER STATISTICS 2020
TABLE 61 EUROPE IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)
TABLE 62 EUROPE IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)
TABLE 63 EUROPE IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)
TABLE 64 EUROPE IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 65 EUROPE IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 66 EUROPE IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)
TABLE 67 EUROPE IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 68 EUROPE IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 69 APAC IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)
TABLE 70 APAC IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)
TABLE 71 APAC IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)
TABLE 72 APAC IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 73 APAC IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 74 APAC IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)
TABLE 75 APAC IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 76 APAC IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 77 COMMERCIAL RT-PCR ASSAY FOR SARS-COV-2 DIAGNOSIS IN MALAYSIA
TABLE 78 COVID-19 STATISTICS IN LATIN AMERICA (2019-2022)
TABLE 79 LATIN IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)
TABLE 80 LATIN IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)
TABLE 81 LATIN IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)
TABLE 82 LATIN IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 83 LATIN IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 84 LATIN IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)
TABLE 85 LATIN IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 86 LATIN AMERICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 87 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)
TABLE 88 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)
TABLE 89 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)
TABLE 90 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 91 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 92 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 (%)
TABLE 93 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 ($ BILLION)
TABLE 94 MIDDLE EAST & AFRICA IN-VITRO DIAGNOSTICS MARKET BY END-USER 2022−2028 (%)
TABLE 95 COMPETITION AMONG MARKET PLAYERS BASED ON TECHNOLOGY
TABLE 96 COMPETITION AMONG MARKET PLAYERS BASED ON TECHNOLOGY ($ BILLION) 2020-2021
TABLE 97 ABBOTT DIAGNOSTIC SEGMENT REVENUE FROM 2019 – 2021 ($ MILLION)
TABLE 98 ABBOTT: MAJOR PRODUCT OFFERINGS
TABLE 99 DANAHER: MAJOR PRODUCT OFFERINGS
TABLE 100 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
TABLE 101 SIEMENS HEALTHINEERS: MAJOR PRODUCT OFFERINGS
TABLE 102 THERMO FISHER SCIENTIFIC: MAJOR PRODUCT OFFERINGS
TABLE 103 ATOMO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 104 ACCELERATE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 105 AGILENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 106 ALTONA DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 107 AMOY DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 108 ARKRAY: MAJOR PRODUCT OFFERINGS
TABLE 109 ACCUBIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 110 AGAPPE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 111 BD: MAJOR PRODUCT OFFERINGS
TABLE 112 BIO-RAD LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 113 BALIO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 114 B&E BIO-TECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 115 BIOMÉRIEUX: MAJOR PRODUCT OFFERINGS
TABLE 116 BIOLYTICAL LABORATORIES: MAJOR PRODUCT OFFERINGS
TABLE 117 BIOSYNEX: MAJOR PRODUCT OFFERINGS
TABLE 118 BIOCARTIS: MAJOR PRODUCT OFFERINGS
TABLE 119 BIOCEPT: MAJOR PRODUCT OFFERINGS
TABLE 120 BIOHIT OYJ: MAJOR PRODUCT OFFERINGS
TABLE 121 BIOMERICA: MAJOR PRODUCT OFFERINGS
TABLE 122 BIOSYSTEMS: MAJOR PRODUCT OFFERINGS
TABLE 123 BIOWAY BIOLOGICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 124 BOULE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 125 CUPID LIMITED: MAJOR PRODUCT OFFERINGS
TABLE 126 CAREDX: MAJOR PRODUCT OFFERINGS
TABLE 127 CHEMBIO DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 128 CLINDIAG SYSTEMS: MAJOR PRODUCT OFFERINGS
TABLE 129 CONTEC MEDICAL SYSTEMS: MAJOR PRODUCT OFFERINGS
TABLE 130 CONVERGENT TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 131 CPC DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 132 CPM SCIENTIFICA: MAJOR PRODUCT OFFERINGS
TABLE 133 CELLAVISION: MAJOR PRODUCT OFFERINGS
TABLE 134 DIALAB: MAJOR PRODUCT OFFERINGS
TABLE 135 DEXCOM: MAJOR PRODUCT OFFERINGS
TABLE 136 DIASORIN: MAJOR PRODUCT OFFERINGS
TABLE 137 DIAGON: MAJOR PRODUCT OFFERINGS
TABLE 138 DIATRON: MAJOR PRODUCT OFFERINGS
TABLE 139 DIRUI: MAJOR PRODUCT OFFERINGS
TABLE 140 DRUCKER DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 141 EDAN INSTRUMENTS: MAJOR PRODUCT OFFERINGS
TABLE 142 EKF DIAGNOSTICS HOLDINGS: MAJOR PRODUCT OFFERINGS
TABLE 143 ELITECHGROUP: MAJOR PRODUCT OFFERINGS
TABLE 144 ERBA DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 145 GENETRON HOLDINGS: MAJOR PRODUCT OFFERINGS
TABLE 146 GENRUI BIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 147 HOLOGIC: MAJOR PRODUCT OFFERINGS
TABLE 148 HIGH TECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 149 HORIBA: MAJOR PRODUCT OFFERINGS
TABLE 150 LINEAR CHEMICALS: MAJOR PRODUCT OFFERINGS
TABLE 151 ILLUMINA: MAJOR PRODUCT OFFERINGS
TABLE 152 INTEC: MAJOR PRODUCT OFFERINGS
TABLE 153 J. MITRA & CO.: MAJOR PRODUCT OFFERINGS
TABLE 154 KILPEST INDIA LIMITED: MAJOR PRODUCT OFFERINGS
TABLE 155 MACCURA BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 156 MEDSOURCE OZONE BIOMEDICALS: MAJOR PRODUCT OFFERINGS
TABLE 157 MERIL LIFE SCIENCES: MAJOR PRODUCT OFFERINGS
TABLE 158 MP BIOMEDICALS: MAJOR PRODUCT OFFERINGS
TABLE 159 NANJING SYNTHGENE MEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 160 NIHON KOHDEN: MAJOR PRODUCT OFFERINGS
TABLE 161 NORMA INSTRUMENTS: MAJOR PRODUCT OFFERINGS
TABLE 162 NOWDIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 163 ORTHO CLINICAL DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 164 OPKO HEALTH: MAJOR PRODUCT OFFERINGS
TABLE 165 ORASURE TECHNOLOGIES: MAJOR PRODUCT OFFERINGS
TABLE 166 PERKIN ELMER: MAJOR PRODUCT OFFERINGS
TABLE 167 PRESTIGE DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 168 QIAGEN: MAJOR PRODUCT OFFERINGS
TABLE 169 QUIDEL: MAJOR PRODUCT OFFERINGS
TABLE 170 SYSMEX: MAJOR PRODUCT OFFERINGS
TABLE 171 SALOFA OY: MAJOR PRODUCT OFFERINGS
TABLE 172 SEASUN BIOMATERIALS: MAJOR PRODUCT OFFERINGS
TABLE 173 SEKISUI DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 174 SFRI: MAJOR PRODUCT OFFERINGS
TABLE 175 SHENZHEN DYMIND BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 176 SHENZHEN ICUBIO BIOMEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 177 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS: MAJOR PRODUCT OFFERINGS
TABLE 178 SHENZHEN PROKAN ELECTRONICS: MAJOR PRODUCT OFFERINGS
TABLE 179 SHENZHEN LANDWIND MEDICAL: MAJOR PRODUCT OFFERINGS
TABLE 180 SINOCARE: MAJOR PRODUCT OFFERINGS
TABLE 181 SPINREACT: MAJOR PRODUCT OFFERINGS
TABLE 182 SURESCREEN DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
TABLE 183 THE BINDING SITE GROUP: MAJOR PRODUCT OFFERINGS
TABLE 184 TRINITY BIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 185 TRIVITRON HEALTHCARE: MAJOR PRODUCT OFFERINGS
TABLE 186 XIAMEN BIOTIME BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
TABLE 187 ZHEJIANG ORIENT GENE BIOTECH: MAJOR PRODUCT OFFERINGS
TABLE 188 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 189 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 190 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 ($ BILLION)
TABLE 191 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY PRODUCT & SERVICES 2022−2028 (%)
TABLE 192 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 ($ BILLION)
TABLE 193 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY TECHNOLOGY 2022−2028 (%)
TABLE 194 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY APPLICATION 2022−2028 ($ BILLION)
TABLE 195 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 196 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022−2028 ($ BILLION)
TABLE 197 GLOBAL IN-VITRO DIAGNOSTICS MARKET BY END-USERS 2022−2028 (%)
TABLE 198 REAGENTS & CONSUMABLES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 199 REAGENTS & CONSUMABLES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 200 INSTRUMENTS/ANALYZERS & SOFTWARE IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 201 INSTRUMENTS/ANALYZERS & SOFTWARE IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 202 SERVICES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 203 SERVICES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 204 IMMUNO & CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 205 IMMUNO & CLINICAL CHEMISTRY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 206 MOLECULAR DIAGNOSTICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 207 MOLECULAR DIAGNOSTICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 208 HEMATOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 209 HEMATOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 210 MICROBIOLOGY & CYTOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 211 MICROBIOLOGY & CYTOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 212 OTHER TECHNOLOGIES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 213 OTHER TECHNOLOGIES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 214 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 215 INFECTIOUS DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 216 DIABETES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 217 DIABETES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 218 CARDIOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 219 CARDIOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 220 ONCOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 221 ONCOLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 222 AUTOIMMUNE DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 223 AUTOIMMUNE DISEASES IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 224 NEPHROLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 225 NEPHROLOGY IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 226 DRUG TESTING IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 227 DRUG TESTING IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 228 OTHER APPLICATIONS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 229 OTHER APPLICATIONS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 230 STANDARD REFERENCE LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 231 STANDARD REFERENCE LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 232 HOSPITALS AFFILIATED LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 233 HOSPITALS AFFILIATED LABS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 234 INDIVIDUALS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 235 INDIVIDUALS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 236 CLINICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 237 CLINICS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
TABLE 238 OTHER END-USERS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 ($ BILLION)
TABLE 239 OTHER END-USERS IN-VITRO DIAGNOSTICS MARKET BY GEOGRAPHY 2022−2028 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
